Gut Liver.  2013 Nov;7(6):712-718.

Continuous Long-Term Entecavir Therapy in Naive Chronic Hepatitis B Patients Showing Partial Virologic Response

Affiliations
  • 1Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea. ihkimmd@jbnu.ac.kr
  • 2Clinical Trial Center, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.

Abstract

BACKGROUND/AIMS
We investigated the efficacy of continuous long-term entecavir 0.5 mg treatment in naive chronic hepatitis B patients showing a partial virologic response (PVR).
METHODS
A total of 227 patients were included. PVR was defined as a more than 1 log10 IU/mL decline in detectable serum hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR; > or =20 IU/mL) at week 48. A complete virologic response (CVR) was defined as undetectable serum HBV DNA by PCR (<20 IU/mL) at week 48.
RESULTS
At week 48, the rate of the PVR was 64/227 (28.2%). Among patients with PVR, the cumulative rates of virologic response (serum HBV DNA <20 IU/mL) at weeks 96 and 144 were 45.2% and 73.8%, respectively. The cumulative rates of genotypic resistance were not significantly different between patients with a PVR and patients with a CVR (p=0.057). However, the cumulative rates of virologic breakthrough were higher in patients with PVR than in patients with CVR (4% vs 0% and 11.2% vs 0% at weeks 96 and 144, respectively; p<0.001).
CONCLUSIONS
Long-term continuous entecavir 0.5 mg treatment in patients with a PVR resulted in an additional virologic response without a significant increase in genotypic resistance. However, the rate of virologic breakthrough was higher in the partial responders.

Keyword

Hepatitis B; Chronic; Entecavir; Partial; Response

MeSH Terms

Adult
Alanine Transaminase/blood
Antiviral Agents/*administration & dosage
DNA, Viral/*blood
Drug Resistance, Viral/genetics
Female
Guanine/administration & dosage/*analogs & derivatives
Hepatitis B e Antigens/blood
*Hepatitis B virus/genetics
Hepatitis B, Chronic/*drug therapy
Humans
Male
Middle Aged
Retrospective Studies
Time Factors
Viral Load
Alanine Transaminase
Antiviral Agents
DNA, Viral
Guanine
Hepatitis B e Antigens
Full Text Links
  • GNL
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr